Algernon Pharmaceuticals Inc. C.AGN

Streetwise Reports:

[C10H12N2]

This Pharmaceutical Company Has Brilliant Concept
Biotechnology / Pharmaceuticals

[C10H12N2]

Those numbers by PennyQueen at Streetwise Capital, as good as they may seem are actually low ball numbers if you use the actual valuation method by Bay Bridge Bio.   Two Phase 1 clinical trials @ $88 Million USD valuation each. Plus One Phase 2 clinical trial @ $249 Million USD equals $415 Million USD Valuation once DMT-Stroke moves to Phase 2 in Q4 2022. As of right now with three Phase

[Pandora]

So we're now back to 12 cents How far do you see it going.

[C10H12N2]

As Far As The Eye Can See

[Pandora]

Looks like they're better off when they don't put out news!

[nodaytrader]

Or at least that the price has nothing to do with the company but is whatever day traders want it to be - regardless of value investors or, indeed, stroke patients, So, I repeat my question. Where the hell are the regulators?

[C10H12N2]

That would have been a good question to ask the CEO at the Q&A yetserday. The buck stops with the CEO IF THEY BELIEVE something nefarious is taking place with stock manipulation. Former Algernon - Breathtec Biomedical was investigated by IIROC and did expose a group of orgainzed manipulators/crooks. Whether anyone went to jail behind it, who knows? What I do know is the stock and the narrative

[nodaytrader]

The endangerment of Algernon by price depression, IMO, would be a public harm to honest investors and sick people who would benefit from Algernon's disease remedies. It is the duty and responsibility of regulators to promote public good, including reducing public harm, by ensuring that the activities they regulate do not result in public harm. That duty would include suggesting changes

[C10H12N2]

Admirable but a moot point once uplisted to Nasdaq. hopefully sooner rather tghan later.